Skip to Main Content
Contribute Try STAT+ Today

Thermo Fisher Scientific announced Thursday that it will buy PPD, a contract-research company for the pharmaceutical and biotech industries, in a deal valued at $17.4 billion, plus the assumption of about $3.5 billion in debt.

The acquisition will allow Waltham-based Thermo Scientific, a leader in laboratory equipment and services, to expand its reach in life sciences. PPD, based in North Carolina, provides services to help drug companies run clinical trials.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.